Form 4 for LGND LIGAND PHARMACEUTICALS INC

Accepted 2023-06-13 00:00:00 ET · period of report 2023-06-09 · accession 0000886163-23-000041 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-06-13	2023-06-09	LGND	KOZARICH JOHN W	Dir	A - Grant	$0.00	+1,142	39.6K	+3%	$0
D	2023-06-13	2023-06-09	LGND	KOZARICH JOHN W	Dir	A - Grant	$0.00	+5,461	5,461	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-06-09	A	A	1,142	$0.00	39,630	D	—	—	(F1) Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.
2	Derivative	Non-Qualified Stock Option (right to buy)	2023-06-09	A	A	5,461	$0.00	5,461	D	$73.76 · — to 2033-06-09	5,461 Common Stock	(F2) Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 9, 2023. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant.